In particular, elacridar effectively potentiated the cytotoxic and anti-proliferative activities of imatinib mesylate against chronic myeloid leukemia (CML) cells overexpressing ABCB1 and ABCG2 [96]. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.